Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

被引：23
|
作者：
Zobniw, Chrystia M. [1 ]
Causebrook, Alanna [2 ]
Fong, Mei Ka [1 ]
机构：
[1] Roswell Pk Canc Inst, Dept Pharm, Elm & Carlton St, Buffalo, NY 14263 USA
[2] Erie Coll Osteopath Med, Sch Pharm, Erie, PA USA
来源：
RESEARCH AND REPORTS IN UROLOGY | 2014年 / 6卷
关键词：
glucocorticoid receptor; CYP17; pipeline; enzalutamide; sipuleucel-T; drug resistance; radium-223; dichloride;
D O I：
10.2147/RRU.S29003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
引用
收藏
页码：97 / 105
页数：9
相关论文
共 50 条
  • [41] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Mohamed Salem
    Jorge A. Garcia
    Current Oncology Reports, 2011, 13 : 92 - 96
  • [42] Comparison of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan
    Ni, Hsueh Fen
    Li, Jian-Ri
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 60 - 60
  • [43] Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone
    Duarte, C.
    Jimeno, A.
    Kessler, E. R.
    DRUGS OF TODAY, 2019, 55 (01) : 5 - 15
  • [44] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [45] Drug approval: Olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer
    Sabouret, Annabelle
    Beuzeboc, Philippe
    BULLETIN DU CANCER, 2023, 110 (04) : 339 - 341
  • [46] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Malavaud, Bernard
    LANCET ONCOLOGY, 2023, 24 (10): : 1056 - 1057
  • [47] Optimal Sequencing of Docetaxel and Abiraterone in Men With Metastatic Castration-Resistant Prostate Cancer
    Maughan, Benjamin L.
    Xhou, Xian C.
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael T.
    Antonarakis, Emmanuel S.
    PROSTATE, 2015, 75 (15): : 1814 - 1820
  • [48] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [49] Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
    Leibowitz-Amit, Raya
    Templeton, Arnoud J.
    Alibhai, Shabbir M.
    Knox, Jennifer J.
    Sridhar, Srikala S.
    Tannock, Ian F.
    Joshua, Anthony M.
    JOURNAL OF GERIATRIC ONCOLOGY, 2015, 6 (01) : 23 - 28
  • [50] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
12345